Mesoblast reports financial results and operational update for half-year ended december 31, 2023

New york, feb. 28, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended december 31, 2023.
MESO Ratings Summary
MESO Quant Ranking